Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Apr;61(4):433-436.
doi: 10.1007/s00108-020-00765-5.

[New treatment options for moderate to severe ulcerative colitis]

[Article in German]
T Kucharzik  1 , S Nitschmann  2
Affiliations
Comment

[New treatment options for moderate to severe ulcerative colitis]

[Article in German]
T Kucharzik et al. Internist (Berl). 2020 Apr.
No abstract available

PubMed Disclaimer

Comment on

  • Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis.
    Sands BE, Sandborn WJ, Panaccione R, O'Brien CD, Zhang H, Johanns J, Adedokun OJ, Li K, Peyrin-Biroulet L, Van Assche G, Danese S, Targan S, Abreu MT, Hisamatsu T, Szapary P, Marano C; UNIFI Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1201-1214. doi: 10.1056/NEJMoa1900750. N Engl J Med. 2019. PMID: 31553833 Clinical Trial.
  • Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
    Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.

LinkOut - more resources